Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Amgen v Sanofi: Big Pharma awaits SCOTUS decision

15 December 2022 As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.

Big Pharma

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

Americas

GSK claims Amgen v Sanofi decision “threatens” innovation

29 April 2021 GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

More on this story

Editor's picks

Editor's picks

More features